

Comparing COVID-19 vaccines for their characteristics, SARS-CoV-2 and variants of concern: a narrative review

Clinical Microbiology and Infection

28, 202-221

DOI: [10.1016/j.cmi.2021.10.005](https://doi.org/10.1016/j.cmi.2021.10.005)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 2 | Limited Impact of Delta Variant's Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population. <i>Viruses</i> , 2021, 13, 2405. | 1.5 | 3 |
| 4 | Haphazard Intentional Sampling in Survey and Allocation Studies on COVID-19 Prevalence and Vaccine Efficacy. <i>Entropy</i> , 2022, 24, 225. | 1.1 | 0 |
| 6 | The Immunologic Profile of Vitamin D and Its Role in Different Immune-Mediated Diseases: An Expert Opinion. <i>Nutrients</i> , 2022, 14, 473. | 1.7 | 13 |
| 7 | SARS-CoV-2 Infection and Lung Regeneration. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0018821. | 5.7 | 24 |
| 8 | Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. <i>Biomedicines</i> , 2022, 10, 338. | 1.4 | 21 |
| 9 | A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein. <i>International Immunopharmacology</i> , 2022, 105, 108565. | 1.7 | 44 |
| 10 | Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. <i>Environmental Research</i> , 2022, 209, 112816. | 3.7 | 189 |
| 11 | COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2313-2336. | 2.7 | 12 |
| 12 | Post-Vaccination SARS-CoV-2 Infections among Health Workers at the University Hospital of Verona, Italy: A Retrospective Cohort Survey. <i>Vaccines</i> , 2022, 10, 272. | 2.1 | 24 |
| 13 | Factors Associated with COVID-19 Vaccine Hesitancy in Mongolia: A Web-Based Cross-Sectional Survey. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12903. | 1.2 | 21 |
| 14 | Adverse reactions and attitudes toward vaccines among young populations one month after receiving a second dose of mRNA-1273 in Japan. <i>Global Health & Medicine</i> , 2022, 4, 141-143. | 0.6 | 1 |
| 15 | Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 350. | 2.1 | 44 |
| 16 | Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-5. | 1.4 | 5 |
| 18 | Development of Flat Warts on the Cheeks after BioNTech-Pfizer BNT162b2 Vaccine: Is There a Correlation?. <i>Vaccines</i> , 2022, 10, 532. | 2.1 | 5 |
| 19 | COVID-19 Infection in Vaccinated Healthcare Professionals. <i>Cureus</i> , 2022, 14, e23386. | 0.2 | 1 |
| 22 | A Survey of Awareness of COVID-19 Knowledge, Willingness and Influencing Factors of COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 524. | 2.1 | 2 |
| 23 | mRNA COVID-19 vaccine and oral lichen planus: A case report. <i>Oral Diseases</i> , 2022, 28, 2624-2626. | 1.5 | 12 |
| 24 | An idiotypic network dysregulation could be related to the pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT) following vaccination with vaccines expressing Spike protein of SARS CoV2. <i>Internal and Emergency Medicine</i> , 2022, 17, 1249-1250. | 1.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 25 | Acute entire colitis and vein thrombosis after COVID-19 mRNA vaccination. <i>Digestive Endoscopy</i> , 2022, 34, 1069-1069. | 1.3 | 1 |
| 26 | The Immune Response, Safety, and Efficacy of Emergency Use Authorization-Granted COVID-19 Vaccines: A Review. <i>Open Microbiology Journal</i> , 2022, 16, . | 0.2 | 1 |
| 27 | Characteristics of the Third COVID-19 Pandemic Wave with Special Focus on Socioeconomic Inequalities in Morbidity, Mortality and the Uptake of COVID-19 Vaccination in Hungary. <i>Journal of Personalized Medicine</i> , 2022, 12, 388. | 1.1 | 12 |
| 28 | Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study. <i>Thyroid</i> , 2022, 32, 505-514. | 2.4 | 35 |
| 29 | Molecular Dynamics and MM-PBSA Analysis of the SARS-CoV-2 Gamma Variant in Complex with the hACE-2 Receptor. <i>Molecules</i> , 2022, 27, 2370. | 1.7 | 10 |
| 30 | Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD. <i>MedComm</i> , 2022, 3, e130. | 3.1 | 18 |
| 31 | Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. <i>Viruses</i> , 2022, 14, 759. | 1.5 | 41 |
| 32 | Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population. <i>Vaccines</i> , 2021, 9, 1435. | 2.1 | 8 |
| 34 | Combination of Acute Exacerbation of Idiopathic Nonspecific Interstitial Pneumonia and Pulmonary Embolism after Booster Anti-COVID-19 Vaccination. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 38 | Comparative Effectiveness of mRNA and Inactivated Whole-Virus Vaccines Against Coronavirus Disease 2019 Infection and Severe Disease in Singapore. <i>Clinical Infectious Diseases</i> , 2022, 75, 1442-1445. | 2.9 | 53 |
| 39 | Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)? <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1077-1082. | 2.5 | 4 |
| 40 | COVID-19 Vaccines: Current and Future Perspectives. <i>Vaccines</i> , 2022, 10, 608. | 2.1 | 26 |
| 41 | A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, . | 0.4 | 62 |
| 43 | Comparison between an in-house SARS-CoV-2 ELISpot and the T-Spot®-Discovery SARS-CoV-2 for the assessment of T cell responses in prior SARS-CoV-2-infected individuals. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105158. | 1.6 | 0 |
| 44 | Autophagy and evasion of the immune system by SARS-CoV-2. Structural features of the non-structural protein 6 from wild type and Omicron viral strains interacting with a model lipid bilayer. <i>Chemical Science</i> , 2022, 13, 6098-6105. | 3.7 | 11 |
| 45 | Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent. <i>Future Virology</i> , 2022, 17, 403-413. | 0.9 | 6 |
| 46 | Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants. <i>Biomedicines</i> , 2022, 10, 996. | 1.4 | 3 |
| 47 | Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1138-1145. | 1.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 48 | A Phase II Study on the Effect of Taurisolo [®] Administered via AEROSol in Hospitalized Patients with Mild to Moderate COVID-19 Pneumonia: The TAEROVID-19 Study. <i>Cells</i> , 2022, 11, 1499. | 1.8 | 6 |
| 49 | Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2068883. | 1.4 | 44 |
| 50 | Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2022, 386, 2084-2096. | 13.9 | 118 |
| 51 | Persistence of immune responses to the Sinopharm/BBIBP [®] CoV vaccine. <i>Immunity, Inflammation and Disease</i> , 2022, 10, . | 1.3 | 20 |
| 52 | New-Onset Acute Kidney Disease Post COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 742. | 2.1 | 12 |
| 53 | Acute Onset of Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Two Weeks After COVID-19 Vaccination With mRNA-1273 With Possible Activation of Parvovirus B19: A Case Report With Literature Review. <i>Cureus</i> , 2022, , . | 0.2 | 3 |
| 54 | Impact of national Covid-19 vaccination Campaign, South Korea. <i>Vaccine</i> , 2022, 40, 3670-3675. | 1.7 | 21 |
| 55 | Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational impacts, concerns, and the possible solutions. <i>Annals of Medicine and Surgery</i> , 2022, 78, 103737. | 0.5 | 33 |
| 56 | Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status. <i>JAMA Network Open</i> , 2022, 5, e229317. | 2.8 | 145 |
| 57 | Development of DNA Vaccine Candidate against SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1049. | 1.5 | 7 |
| 58 | Hijacking of Cellular Functions by Severe Acute Respiratory Syndrome Coronavirus-2. Permeabilization and Polarization of the Host Lipid Membrane by Viroporins. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 4642-4649. | 2.1 | 3 |
| 59 | SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol. <i>BMJ Open</i> , 2022, 12, e061345. | 0.8 | 2 |
| 60 | An epidemiological study on face masks and acne in a Nigerian population. <i>PLoS ONE</i> , 2022, 17, e0268224. | 1.1 | 7 |
| 61 | Defining SARS-CoV-2 breakthrough infection needing hospitalization in mass vaccination era: from disease-centered to patient-centered care.. <i>Acta Biomedica</i> , 2022, 93, e2022182. | 0.2 | 3 |
| 62 | Combination of acute exacerbation of idiopathic nonspecific interstitial pneumonia and pulmonary embolism after booster anti-COVID-19 vaccination. <i>Respiratory Medicine Case Reports</i> , 2022, 38, 101674. | 0.2 | 3 |
| 63 | Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine. <i>Immunity and Ageing</i> , 2022, 19, . | 1.8 | 9 |
| 64 | Receptor binding domain proteins of SARS-CoV-2 variants produced in <i>Nicotiana benthamiana</i> elicit neutralizing antibodies against variants of concern. <i>Journal of Medical Virology</i> , 2022, 94, 4265-4276. | 2.5 | 10 |
| 65 | Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1382-1388. | 2.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 66 | Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants. <i>Scientific Reports</i> , 2022, 12, . | 1.6 | 53 |
| 67 | COVID-19-Current Therapeutical Approaches and Future Perspectives. <i>Processes</i> , 2022, 10, 1053. | 1.3 | 1 |
| 68 | Evaluation of the Real-World Effectiveness of Vaccines against COVID-19 at a Local Level: Protocol for a Test-Negative Caseâ€“Control Study. <i>Vaccines</i> , 2022, 10, 822. | 2.1 | 2 |
| 69 | Immunogenicity and Reactogenicity of the Booster Dose of COVID-19 Vaccines and Related Factors: A Panel Study from the General Population in Serbia. <i>Vaccines</i> , 2022, 10, 838. | 2.1 | 8 |
| 70 | Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, . | 1.2 | 5 |
| 71 | A Calculator for COVID-19 Severity Prediction Based on Patient Risk Factors and Number of Vaccines Received. <i>Microorganisms</i> , 2022, 10, 1238. | 1.6 | 2 |
| 72 | The Effectiveness of COVID-19 Vaccines in Preventing Hospitalizations During the Delta Wave: A Patient-Population Study at a Major Referral Center. <i>Cureus</i> , 2022, , . | 0.2 | 0 |
| 73 | Public Perception of SARS-CoV-2 Vaccines Among Psoriasis Patients in Social Media: Content, Sentiment, and Engagement Analysis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 0, , 247553032211100. | 0.3 | 0 |
| 74 | Immune system changes in those with hypertension when infected with SARS-CoV-2. <i>Cellular Immunology</i> , 2022, 378, 104562. | 1.4 | 2 |
| 75 | Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7233. | 1.2 | 5 |
| 76 | Vaccine Effectiveness of CanSino (Adv5-nCoV) Coronavirus Disease 2019 (COVID-19) Vaccine Among Childcare Workersâ€“Mexico, Marchâ€“December 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, S167-S173. | 2.9 | 7 |
| 77 | Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal. <i>Journal of Computer-Aided Molecular Design</i> , 2022, 36, 483-505. | 1.3 | 4 |
| 78 | Self-Reported COVID-19 Vaccinesâ€™ Side Effects among Patients Treated with Biological Therapies in Saudi Arabia: A Multicenter Cross-Sectional Study. <i>Vaccines</i> , 2022, 10, 977. | 2.1 | 0 |
| 79 | Route, origin & valence matter: towards sophisticated next-generation vaccines to cope with the COVID-19 pandemic. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, . | 7.1 | 1 |
| 80 | Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review. <i>Journal of Medical Virology</i> , 2022, 94, 4628-4643. | 2.5 | 17 |
| 81 | SARS-CoV-2: phenotype, genotype, and characterization of different variants. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, . | 2.7 | 12 |
| 82 | Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine. <i>Vaccines</i> , 2022, 10, 929. | 2.1 | 3 |
| 83 | Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1273-1278. | 0.8 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 84 | Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths. <i>Journal of Personalized Medicine</i> , 2022, 12, 995. | 1.1 | 9 |
| 85 | COVID-19 Vaccines and Autoimmune Hematologic Disorders. <i>Vaccines</i> , 2022, 10, 961. | 2.1 | 23 |
| 86 | Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19. <i>Annals of Internal Medicine</i> , 2022, 175, 1126-1134. | 2.0 | 47 |
| 87 | Rise of monkeypox: Lessons from COVID-19 pandemic to mitigate global health crises. <i>Annals of Medicine and Surgery</i> , 2022, 79, . | 0.5 | 20 |
| 88 | Structural basis of Omicron immune evasion: A comparative computational study. <i>Computers in Biology and Medicine</i> , 2022, 147, 105758. | 3.9 | 6 |
| 89 | A Comparative Analysis of a Self-Reported Adverse Events Analysis after Receiving One of the Available SARS-CoV-2 Vaccine Schemes in Ecuador. <i>Vaccines</i> , 2022, 10, 1047. | 2.1 | 5 |
| 90 | Immunogenicity and efficacy of Ad26.<sc>COV2</sc>.S: An adenoviral vectorâ€‘based <sc>COVID</sc>â€‘19 vaccine. <i>Immunological Reviews</i> , 2022, 310, 47-60. | 2.8 | 10 |
| 91 | Riding the Pandemic Wavesâ€‘ Lessons to Be Learned from the COVID-19 Crisis Management in Romania. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 122. | 0.9 | 5 |
| 92 | Duration of infectious shedding of SARS-CoV-2 Omicron variant and its relation with symptoms. <i>Clinical Microbiology and Infection</i> , 2023, 29, 221-224. | 2.8 | 20 |
| 93 | Pseudoscience andâ€‘fraudulent products for COVID-19 management. <i>Environmental Science and Pollution Research</i> , 2022, 29, 62887-62912. | 2.7 | 15 |
| 94 | Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies. <i>Vaccines</i> , 2022, 10, 1067. | 2.1 | 8 |
| 95 | Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences. <i>Vaccines</i> , 2022, 10, 1068. | 2.1 | 9 |
| 96 | COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants. <i>Current Pharmaceutical Design</i> , 2022, 28, 2901-2913. | 0.9 | 3 |
| 97 | Advances in COVID-19 Vaccines and New Coronavirus Variants. <i>Frontiers in Medicine</i> , 0, 9, . | 1.2 | 4 |
| 99 | A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. <i>Pharmaceutical Research</i> , 2022, 39, 2119-2134. | 1.7 | 10 |
| 100 | The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1636-1643. | 2.8 | 3 |
| 101 | SARS-CoV-2 Achieves Immune Escape by Destroying Mitochondrial Quality: Comprehensive Analysis of the Cellular Landscapes of Lung and Blood Specimens From Patients With COVID-19. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 16 |
| 102 | The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis. <i>Frontiers in Public Health</i> , 0, 10, . | 1.3 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 103 | Maresin-1 and its receptors ROR1/LGR6 as potential therapeutic target for respiratory diseases. <i>Pharmacological Research</i> , 2022, 182, 106337. | 3.1 | 9 |
| 104 | Network analysis for elucidating the mechanisms of Shenfu injection in preventing and treating COVID-19 combined with heart failure. <i>Computers in Biology and Medicine</i> , 2022, 148, 105845. | 3.9 | 3 |
| 105 | Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study). <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 25 |
| 106 | Exploration of molecular targets and mechanisms of Chinese medicinal formula <i>Acacia Catechu</i> in the treatment of COVID-19 by a systems pharmacology strategy. <i>Phytotherapy Research</i> , 2022, 36, 4210-4229. | 2.8 | 7 |
| 107 | COVID-19 Vaccine for Children: Vaccination Willingness of Parents and Its Associated Factors – A Network Analysis. <i>Vaccines</i> , 2022, 10, 1155. | 2.1 | 7 |
| 108 | The public's attitude to and acceptance of periodic doses of the COVID-19 vaccine: A survey from Jordan. <i>PLoS ONE</i> , 2022, 17, e0271625. | 1.1 | 8 |
| 109 | Transmissibility of SARS-CoV-2 B.1.1.214 and Alpha Variants during 4 COVID-19 Waves, Kyoto, Japan, January 2020–June 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, . | 2.0 | 4 |
| 110 | COVID-19 After Vaccination in Lung Transplant Recipients: Real-Life Data. <i>Experimental and Clinical Transplantation</i> , 0, , . | 0.2 | 0 |
| 111 | Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants. <i>Vaccines</i> , 2022, 10, 1208. | 2.1 | 5 |
| 112 | Postural orthostatic tachycardia syndrome after mRNA COVID-19 vaccine. <i>Clinical Autonomic Research</i> , 2022, 32, 307-311. | 1.4 | 15 |
| 113 | Textiles Functionalized with Copper Oxides: A Sustainable Option for Prevention of COVID-19. <i>Polymers</i> , 2022, 14, 3066. | 2.0 | 3 |
| 114 | Association Between Vaccination and Acute Myocardial Infarction and Ischemic Stroke After COVID-19 Infection. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 887. | 3.8 | 72 |
| 115 | SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients – a comparative long term post-infection study. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 4 |
| 116 | Prevalence and factors associated with not receiving the booster dose of the COVID-19 vaccine in adults in Latin America and the Caribbean. <i>Travel Medicine and Infectious Disease</i> , 2022, , 102409. | 1.5 | 7 |
| 117 | De Novo Vasculitis after COVID-19 Vaccination. <i>Current Rheumatology Reviews</i> , 2023, 19, 151-158. | 0.4 | 3 |
| 118 | Intensity of Humoral Immune Responses, Adverse Reactions, and Post-Vaccination Morbidity after Adenovirus Vector-Based and mRNA Anti-COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 1268. | 2.1 | 4 |
| 119 | Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-13. | 0.7 | 5 |
| 120 | Indoxyl Sulfate Alters the Humoral Response of the ChAdOx1 COVID-19 Vaccine in Hemodialysis Patients. <i>Vaccines</i> , 2022, 10, 1378. | 2.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 121 | A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health. <i>Biomedicines</i> , 2022, 10, 2050. | 1.4 | 8 |
| 122 | Influenza vaccination coverage among health-care workers during the COVID-19 epidemic in 2020/2021 influenza season: Evidence from a web-based survey in northwestern China. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, . | 1.4 | 2 |
| 123 | Two Years into the COVID-19 Pandemic: Lessons Learned. <i>ACS Infectious Diseases</i> , 2022, 8, 1758-1814. | 1.8 | 47 |
| 124 | Time-Varying Effect of Hybrid Immunity on the Risk of Breakthrough Infection after Booster Dose of mRNA COVID-19 Vaccine: The MOSAICO Study. <i>Vaccines</i> , 2022, 10, 1353. | 2.1 | 9 |
| 125 | Impact of COVID-19 Vaccination on Healthcare Worker Infection Rate and Outcome during SARS-CoV-2 Omicron Variant Outbreak in Hong Kong. <i>Vaccines</i> , 2022, 10, 1322. | 2.1 | 7 |
| 126 | Establishment of a protein thermal shift chip (PTSC) for COVID-19 and exploration of the future of protein chips in pharmacology. , 2022, 1, . | | 0 |
| 127 | Structural and Phylogenetic Analysis of SARS-CoV-2 Spike Glycoprotein from the Most Widespread Variants. <i>Life</i> , 2022, 12, 1245. | 1.1 | 7 |
| 128 | The actual status of hospitals as COVID-19 vaccination Clinic in China and safety monitoring of inactivated vaccine: a cross-sectional study. <i>Disaster Medicine and Public Health Preparedness</i> , 0, , 1-23. | 0.7 | 1 |
| 129 | Eosinophilâ€rich linear <scp>IgA</scp> bullous dermatosis induced by <scp>mRNA COVID</scp> â€19 booster vaccine. <i>Journal of Cutaneous Pathology</i> , 0, , . | 0.7 | 4 |
| 130 | The Race for Global Equitable Access to COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 1306. | 2.1 | 26 |
| 131 | Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128. | 1.7 | 9 |
| 132 | Exploiting reverse vaccinology approach for the design of a multiepitope subunit vaccine against the major SARS-CoV-2 variants. <i>Computational Biology and Chemistry</i> , 2022, 101, 107754. | 1.1 | 7 |
| 133 | Six Pivotal Lessons Learned in South Korea for Whole-of-Government Approach to Successful COVID-19 Vaccine Rollout in Planetary Health. <i>OMICS A Journal of Integrative Biology</i> , 2022, 26, 567-579. | 1.0 | 2 |
| 134 | SARS-CoV-2 mRNA-vaccine candidate; COrE nAPCINÂ®, induces robust humoral and cellular immunity in mice and non-human primates. <i>Npj Vaccines</i> , 2022, 7, . | 2.9 | 5 |
| 135 | Metabolic and Proteomic Profiles Associated with Immune Responses Induced by Different Inactivated SARS-CoV-2 Vaccine Candidates. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10644. | 1.8 | 1 |
| 136 | Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?. <i>International Journal of Infectious Diseases</i> , 2022, 124, 1-10. | 1.5 | 12 |
| 137 | BBIBP-CorV Vaccination Reduces COVID-19 Severity Rate and Accelerates Anti-Viral Antibody Responses in Heterologous Omicron Infection. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 138 | COVID-19 post-vaccination in healthcare workers and vaccine effectiveness, Brazil, 2021. <i>Clinics</i> , 2022, 77, 100109. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 139 | Wie hat das Coronavirus unsere sichere Welt der Selbstverständlichkeiten verändert?. , 2022, , 193-220. | | 0 |
| 140 | The life and death of RNA across temperatures. Computational and Structural Biotechnology Journal, 2022, 20, 4325-4336. | 1.9 | 16 |
| 141 | Laryngotracheal Stenosis Following Intubation for COVID-19 Pneumonia: A Report of Two Cases. International Journal of Otolaryngology and Head & Neck Surgery, 2022, 11, 234-241. | 0.1 | 0 |
| 142 | Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population. Scientific Reports, 2022, 12, . | 1.6 | 3 |
| 143 | The Willingness to get Vaccinated Against SARS-CoV-2 Virus among Southeast Asian Countries: Does the Vaccine Brand Matter?. Applied Research in Quality of Life, 2023, 18, 765-793. | 1.4 | 5 |
| 144 | Characteristics and Roles of T Follicular Helper Cells in SARS-CoV-2 Vaccine Response. Vaccines, 2022, 10, 1623. | 2.1 | 2 |
| 145 | Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern. Frontiers in Immunology, 0, 13, . | 2.2 | 6 |
| 146 | COVID-19 and isolation: Risks and implications in the scenario of new variants. Brazilian Journal of Infectious Diseases, 2022, 26, 102703. | 0.3 | 2 |
| 147 | Phytotherapy and Dietotherapy of COVID-19 – An Online Survey Results from Central Part of Balkan Peninsula. Healthcare (Switzerland), 2022, 10, 1678. | 1.0 | 6 |
| 148 | Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic. Frontiers in Immunology, 0, 13, . | 2.2 | 2 |
| 149 | Self-Assembling Protein Nanoparticles in the Design of Vaccines: 2022 Update. Vaccines, 2022, 10, 1447. | 2.1 | 4 |
| 150 | Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein. International Journal of Molecular Sciences, 2022, 23, 10904. | 1.8 | 8 |
| 151 | Engineering the common cold to be a live-attenuated SARS-CoV-2 vaccine. Frontiers in Immunology, 0, 13, . | 2.2 | 5 |
| 153 | Determinants of anti-S immune response at 6 months after COVID-19 vaccination in a multicentric European cohort of healthcare workers – ORCHESTRA project. Frontiers in Immunology, 0, 13, . | 2.2 | 16 |
| 154 | SARS-CoV-2 Variant Surveillance in Genomic Medicine Era. Infectious Diseases, 0, , . | 4.0 | 0 |
| 156 | Extension of Interval-Valued Fermatean Fuzzy TOPSIS for Evaluating and Benchmarking COVID-19 Vaccines. Mathematics, 2022, 10, 3514. | 1.1 | 13 |
| 157 | High mortality and morbidity among vaccinated residents infected with the SARS-CoV-2 Omicron variant during an outbreak in a nursing home in Kyoto City, Japan. American Journal of Infection Control, 2023, 51, 800-806. | 1.1 | 7 |
| 158 | A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines. DARU, Journal of Pharmaceutical Sciences, 0, , . | 0.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 159 | Clinical characteristics in immune thrombocytopenia patients after COVID-19 vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, . | 1.4 | 6 |
| 160 | Preliminary Analysis of the Effects of Ad26.COVS Vaccination on CT Findings and High Intensive Care Admission Rates of COVID-19 Patients. <i>Tomography</i> , 2022, 8, 2403-2410. | 0.8 | 0 |
| 161 | High-yield production in <i>Escherichia coli</i> and convenient purification of a candidate vaccine against SARS-CoV-2. <i>Biotechnology Letters</i> , 2022, 44, 1313-1322. | 1.1 | 3 |
| 162 | The influence of COVID-19 infection-associated immune response on the female reproductive system. <i>Biology of Reproduction</i> , 2023, 108, 172-182. | 1.2 | 14 |
| 163 | COVID-19 outcomes in sickle cell disease and sickle cell trait. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101382. | 0.7 | 1 |
| 164 | Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 4 |
| 165 | Analysis of Adverse Effects of COVID-19 Vaccines Experienced by Healthcare Workers at Guizhou Provincial Staff Hospital, China. <i>Vaccines</i> , 2022, 10, 1449. | 2.1 | 2 |
| 166 | Association between Mutations in Papain-like Protease (PLpro) of SARS-CoV-2 with COVID-19 Clinical Outcomes. <i>Pathogens</i> , 2022, 11, 1008. | 1.2 | 2 |
| 167 | Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials. <i>Frontiers in Medicine</i> , 0, 9, . | 1.2 | 10 |
| 168 | Potential therapeutic strategies for quercetin targeting critical pathological mechanisms associated with colon adenocarcinoma and COVID-19. <i>Frontiers in Pharmacology</i> , 0, 13, . | 1.6 | 2 |
| 169 | Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants. <i>Vaccines</i> , 2022, 10, 1596. | 2.1 | 1 |
| 170 | Real-world effectiveness and protection of SARS-CoV-2 vaccine among patients hospitalized for COVID-19 in Xi'an, China, December 8, 2021, to January 20, 2022: A retrospective study. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 2 |
| 171 | Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 5 |
| 172 | The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial. <i>Frontiers in Medicine</i> , 0, 9, . | 1.2 | 16 |
| 173 | Is Myasthenia Gravis a Real Complication of the COVID-19 Vaccine? A Case Report-Based Systematic Review. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-7. | 0.7 | 6 |
| 174 | Current understanding on long non-coding RNAs in immune response to COVID-19. <i>Virus Research</i> , 2023, 323, 198956. | 1.1 | 5 |
| 175 | Knowledge, attitudes, and behaviors toward COVID-19 vaccination in a sample of Italian healthcare workers. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, . | 1.4 | 10 |
| 176 | A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan. <i>International Journal of Biological Macromolecules</i> , 2022, 222, 661-670. | 3.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 177 | SARS-CoV-2 antibody determination in a vaccinated and recovered cohort in Austria. <i>Clinical Immunology Communications</i> , 2022, 2, 136-141. | 0.5 | 1 |
| 178 | Anaphylaxis is rare due to CoronaVac in a population of healthcare workers. <i>Asia Pacific Allergy</i> , 2022, 12, e35. | 0.6 | 3 |
| 179 | Clinical characteristics of 1139 mild cases of the SARS-CoV-2 Omicron variant infected patients in Shanghai. <i>Journal of Medical Virology</i> , 2023, 95, . | 2.5 | 16 |
| 180 | Adult-Onset Still's Disease following Coronavirus 2 (SARS-CoV-2) Vaccination: A Case Report. <i>Vaccines</i> , 2022, 10, 1687. | 2.1 | 6 |
| 181 | Scientific Integrity Requires Publishing Rebuttals and Retracting Problematic Papers. <i>Stem Cell Reviews and Reports</i> , 2023, 19, 568-572. | 1.7 | 4 |
| 182 | Effector-Memory B-Lymphocytes and Follicular Helper T-Lymphocytes as Central Players in the Immune Response in Vaccinated and Nonvaccinated Populations against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 1761. | 2.1 | 2 |
| 183 | Metabolic Responses and Pathway Changes of Vero Cells under High-Vitamin B Medium. <i>Vaccines</i> , 2022, 10, 1787. | 2.1 | 0 |
| 184 | Caregivers' experiences and perspectives on caring for the elderly during the COVID-19 pandemic: A qualitative systematic review. <i>Journal of Nursing Management</i> , 2022, 30, 3972-3995. | 1.4 | 3 |
| 185 | Improving the Detection Sensitivity of a New Rapid Diagnostic Technology for Severe Acute Respiratory Syndrome Coronavirus 2 Using a Trace Amount of Saliva. <i>Diagnostics</i> , 2022, 12, 2568. | 1.3 | 1 |
| 186 | Do we miss rare adverse events induced by COVID-19 vaccination?. <i>Frontiers in Medicine</i> , 0, 9, . | 1.2 | 8 |
| 187 | The Comparative Superiority of SARS-CoV-2 Antibody Response in Different Immunization Scenarios. <i>Journal of Personalized Medicine</i> , 2022, 12, 1756. | 1.1 | 2 |
| 188 | Demographics and Clinical Characteristics of COVID-19-vaccinated Patients Admitted to ICU: A Multicenter Cohort Study from India (PostCoVac Study-COVID Group). <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 1184-1191. | 0.3 | 4 |
| 189 | Prerequisite for COVID-19 Prediction: A Review on Factors Affecting the Infection Rate. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12997. | 1.2 | 3 |
| 190 | Mental health and fatigue status of the medical workforce during the COVID-19 outbreak in the Yangzhou city, China. <i>Frontiers in Psychiatry</i> , 0, 13, . | 1.3 | 1 |
| 192 | Severity and Mortality Predictors of COVID-19 Patients with Thrombotic Events-Evidence from the "COVID-One" Hospital in Albania. <i>Vaccines</i> , 2022, 10, 1851. | 2.1 | 0 |
| 193 | A systematic review of current status and challenges of vaccinating children against SARS-CoV-2. <i>Journal of Infection and Public Health</i> , 2022, 15, 1212-1224. | 1.9 | 2 |
| 194 | Risk of Severe COVID-19 in Non-Adherent OSA Patients. <i>Patient Preference and Adherence</i> , 0, Volume 16, 3069-3079. | 0.8 | 2 |
| 195 | Assessment of cell-mediated immune responses to SARS-CoV-2 in Syrian hamsters. <i>Meditinskii Akademicheskii Zhurnal</i> , 2022, 2, 215-220. | 0.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 196 | Non-replicative antibiotic resistance-free DNA vaccine encoding S and N proteins induces full protection in mice against SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 4 |
| 197 | Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. <i>Vaccines</i> , 2022, 10, 1865. | 2.1 | 8 |
| 198 | Dual activation profile of monocytes is associated with protection in Mexican patients during SARS-CoV-2 disease. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 7905-7916. | 1.7 | 1 |
| 199 | Identification of COVID-19 severity biomarkers based on feature selection on single-cell RNA-Seq data of CD8+ T cells. <i>Frontiers in Genetics</i> , 0, 13, . | 1.1 | 5 |
| 200 | A potent, broadly protective vaccine against SARS-CoV-2 variants of concern. <i>Npj Vaccines</i> , 2022, 7, . | 2.9 | 8 |
| 202 | COVID-19 vaccine hesitancy and short-term and long-term intentions among unvaccinated young adults: a mixed-method approach. <i>BMC Public Health</i> , 2022, 22, . | 1.2 | 3 |
| 203 | Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities. <i>Npj Vaccines</i> , 2022, 7, . | 2.9 | 10 |
| 204 | A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 2 |
| 205 | Emerging Multiplex Nucleic Acid Diagnostic Tests for Combating COVID-19. <i>Biosensors</i> , 2022, 12, 978. | 2.3 | 5 |
| 206 | Characterization and analysis of linear epitopes corresponding to SARS-CoV-2 outbreak in Jilin Province, China. <i>Journal of Medical Virology</i> , 2023, 95, . | 2.5 | 4 |
| 207 | Effect of vaccination against Covid-19 one year after its introduction in Brazil. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2022, 8, . | 0.9 | 3 |
| 208 | Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. <i>Journal of Infection and Public Health</i> , 2023, 16, 4-14. | 1.9 | 105 |
| 209 | Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax™) after homologous and heterologous two-dose regimens. <i>International Journal of Infectious Diseases</i> , 2023, 126, 64-72. | 1.5 | 12 |
| 210 | SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses. <i>AIMS Microbiology</i> , 2022, 8, 422-453. | 1.0 | 1 |
| 211 | Invasive Pneumococcal Disease and COVID-19 Coinfection: A Series of Cases Admitted to an Intensive Care Unit. <i>Cureus</i> , 2022, , . | 0.2 | 0 |
| 212 | Targeting the Complement-Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14340. | 1.8 | 7 |
| 213 | Commentary on "Lung Transplantation for COVID-19 Pulmonary Sequelae: Beautiful Story, Already History?". <i>Transplantation</i> , 0, Publish Ahead of Print, . | 0.5 | 0 |
| 214 | High Anti-CoV2S Antibody Levels at Hospitalization Are Associated with Improved Survival in Patients with COVID-19 Vaccine Breakthrough Infection. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 15581. | 1.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 215 | A Case of Purpura Annularis Telangiectodes of Majocchi after Anti-SARS-CoV-2 Pfizer-BioNTech Vaccine: Is There an Association?. <i>Vaccines</i> , 2022, 10, 1972. | 2.1 | 2 |
| 216 | SARS-CoV-2 in brief: from virus to prevention. <i>Osong Public Health and Research Perspectives</i> , 2022, 13, 394-406. | 0.7 | 1 |
| 217 | Determinants of Anti-S Immune Response at 9 Months after COVID-19 Vaccination in a Multicentric European Cohort of Healthcare Workersâ€”ORCHESTRA Project. <i>Viruses</i> , 2022, 14, 2657. | 1.5 | 5 |
| 218 | Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 528-540. | 1.4 | 8 |
| 219 | Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants. <i>Infectious Disease Reports</i> , 2022, 14, 996-1003. | 1.5 | 2 |
| 221 | Association of dual COVID-19 and seasonal influenza vaccination with COVID-19 infection and disease severity. <i>Vaccine</i> , 2023, 41, 875-878. | 1.7 | 9 |
| 222 | Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery. <i>Antiviral Research</i> , 2023, 210, 105506. | 1.9 | 4 |
| 223 | Healthcare workersâ€™ perspectives on the COVID-19 vaccine and boosters for themselves, their patients, and their communities: a mixed methods study. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2024, 32, 123-136. | 0.8 | 2 |
| 224 | Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia. <i>Vaccines</i> , 2022, 10, 2144. | 2.1 | 1 |
| 225 | Maternal and neonatal safety of COVID-19 vaccination during the peri-pregnancy period: A prospective study. <i>Journal of Medical Virology</i> , 2023, 95, . | 2.5 | 6 |
| 226 | Transplantation Amid a Pandemic: The Fall and Rise of Kidney Transplantation in the United States. <i>Transplantation Direct</i> , 2023, 9, e1423. | 0.8 | 1 |
| 227 | Inhalable neutralizing antibodies â€” promising approach to combating respiratory viral infections. <i>Trends in Pharmacological Sciences</i> , 2023, 44, 85-97. | 4.0 | 8 |
| 228 | The Influence of Nutrition and Physical Activity on Exercise Performance after Mild COVID-19 Infection in Endurance Athletes-CESAR Study. <i>Nutrients</i> , 2022, 14, 5381. | 1.7 | 6 |
| 230 | Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review. <i>Expert Review of Vaccines</i> , 2023, 22, 35-53. | 2.0 | 8 |
| 231 | Comparison of the Basic Reproduction Numbers for COVID-19 through Four Waves of the Pandemic in Vietnam. <i>International Journal of Translational Medicine</i> , 2023, 3, 1-11. | 0.1 | 0 |
| 232 | Peripheral Nervous System Adverse Events after the Administration of mRNA Vaccines: A Systematic Review and Meta-Analysis of Large-Scale Studies. <i>Vaccines</i> , 2022, 10, 2174. | 2.1 | 3 |
| 234 | Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 16902-16917. | 2.9 | 15 |
| 235 | Neurological complications of COVID-19. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2023, 116, 161-180. | 0.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 236 | Indole-3-carbinol in vitro antiviral activity against SARS-Cov-2 virus and in vivo toxicity. <i>Cell Death Discovery</i> , 2022, 8, . | 2.0 | 6 |
| 237 | Polymeric Materials as Indispensable Tools to Fight RNA Viruses: SARS-CoV-2 and Influenza A. <i>Bioengineering</i> , 2022, 9, 816. | 1.6 | 0 |
| 238 | Targeting SARS-CoV-2 and host cell receptor interactions. <i>Antiviral Research</i> , 2023, 210, 105514. | 1.9 | 9 |
| 239 | Downregulation of the Protein C Signaling System Is Associated with COVID-19 Hypercoagulabilityâ€”A Single-Cell Transcriptomics Analysis. <i>Viruses</i> , 2022, 14, 2753. | 1.5 | 3 |
| 240 | Immediate and 6-month seizure outcomes following first and second SARS-CoV2 mRNA vaccinations: A multicenter study with a nationwide survey. <i>Epilepsy and Behavior</i> , 2023, 139, 109070. | 0.9 | 1 |
| 241 | The Frequency and Characteristics of Severe Liver-Related Adverse Events in Patients with Chronic Liver Diseases after Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2: A Retrospective Study. <i>Gastrointestinal Disorders</i> , 2023, 5, 15-27. | 0.4 | 0 |
| 242 | The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19. <i>Journal of Inflammation Research</i> , 0, Volume 16, 145-160. | 1.6 | 5 |
| 243 | Adverse Effects of Sinopharm COVID-19 Vaccine among Vaccinated Medical Students and Health Care Workers. <i>Vaccines</i> , 2023, 11, 105. | 2.1 | 5 |
| 244 | Satisfaction With Life Among Vaccinated Turkish People. <i>European Journal of Psychology Open</i> , 2022, 81, 79-87. | 0.5 | 1 |
| 247 | COVID-19: A Comprehensive Review on Cardiovascular Alterations, Immunity, and Therapeutics in Older Adults. <i>Journal of Clinical Medicine</i> , 2023, 12, 488. | 1.0 | 5 |
| 248 | Immune profile of healthcare professionals six months after vaccination or exposure to SARSâ€CoVâ€2 in Angola. <i>Health Science Reports</i> , 2023, 6, . | 0.6 | 0 |
| 249 | CRISPR/Cas9 therapeutics: progress and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, . | 7.1 | 73 |
| 250 | Teaching vaccine development in schools: Learnings from a survey and curriculum design for a course. <i>Frontiers in Education</i> , 0, 7, . | 1.2 | 0 |
| 251 | Temporal trends of COVID-19 antibodies in vaccinated healthcare workers undergoing repeated serological sampling: An individual-level analysis within 13 months in the ORCHESTRA cohort. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 1 |
| 252 | Ventilator Acquired Pneumonia in COVID-19 ICU Patients: A Retrospective Cohort Study during Pandemia in France. <i>Journal of Clinical Medicine</i> , 2023, 12, 421. | 1.0 | 5 |
| 253 | Biobran/MGN-3, an Arabinoxylan Rice Bran, Protects against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An In Vitro and In Silico Study. <i>Nutrients</i> , 2023, 15, 453. | 1.7 | 7 |
| 255 | Screening and confirmation tests for SARS-CoV-2: benefits and drawbacks. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2023, 12, . | 0.8 | 5 |
| 256 | From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114208. | 2.5 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 257 | COVID-19 vaccination hesitancy is not all a conspiracy theory: A qualitative study from Iran. <i>Acta Psychologica</i> , 2023, 233, 103839. | 0.7 | 1 |
| 258 | Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe. <i>Viruses</i> , 2023, 15, 133. | 1.5 | 1 |
| 259 | T Cell Immune Responses against SARS-CoV-2 in the With Corona Era. <i>Biomedical Science Letters</i> , 2022, 28, 211-222. | 0.0 | 0 |
| 261 | COVID-19: Epidemiology, Virology, Transmission, and Prevention. , 2022, 2, 1-5. | | 0 |
| 262 | COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study. <i>Lancet Microbe</i> , The, 2023, 4, e149-e158. | 3.4 | 5 |
| 263 | Association between vaccination status and COVID-19-related health outcomes among community-dwelling COVID-19 patients in Nara, Japan. <i>Environmental Health and Preventive Medicine</i> , 2023, 28, 7-7. | 1.4 | 4 |
| 264 | A Systematic Review on the Safety and Efficacy of COVID-19 Vaccines Approved in Saudi Arabia. <i>Vaccines</i> , 2023, 11, 281. | 2.1 | 6 |
| 265 | mRNA From COVID-19 Treatment to Cancer Immunotherapy. <i>Biomedicines</i> , 2023, 11, 308. | 1.4 | 3 |
| 266 | Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi. <i>Vaccines</i> , 2023, 11, 299. | 2.1 | 5 |
| 268 | Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study. <i>Vaccines</i> , 2023, 11, 247. | 2.1 | 7 |
| 269 | COVID-19, SARS-CoV-2 Vaccination, and Human Herpesviruses Infections. <i>Vaccines</i> , 2023, 11, 232. | 2.1 | 4 |
| 270 | Humoral Immune Response to CoronaVac in Turkish Adults. <i>Vaccines</i> , 2023, 11, 216. | 2.1 | 1 |
| 271 | Perceptions of COVID-19 risk during the pandemic: perspectives from people seeking medication for opioid use disorder. <i>Annals of Medicine</i> , 2023, 55, 480-489. | 1.5 | 1 |
| 272 | Thrombotic thrombocytopenic purpura and mushroom-shaped red blood cells secondary to COVID-19: A case report. <i>Hematology, Transfusion and Cell Therapy</i> , 2023, , . | 0.1 | 0 |
| 273 | The Deceptive COVID-19: Lessons from Common Molecular Diagnostics and a Novel Plan for the Prevention of the Next Pandemic. <i>Diseases (Basel, Switzerland)</i> , 2023, 11, 20. | 1.0 | 5 |
| 274 | Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models. <i>Vaccines</i> , 2023, 11, 318. | 2.1 | 4 |
| 275 | Nanotechnology and materials science help fight against SARS-CoV-2. , 2023, , 295-321. | | 0 |
| 276 | Impact of antibody-level on viral shedding in B.1.617.2 (Delta) variant-infected patients analyzed using a joint model of longitudinal and time-to-event data. <i>Mathematical Biosciences and Engineering</i> , 2023, 20, 8875-8891. | 1.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 277 | Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro. <i>Animal Models and Experimental Medicine</i> , 2023, 6, 51-56. | 1.3 | 2 |
| 278 | SARS-CoV-2 nucleocapsid: Biological functions and implication for disease diagnosis and vaccine design. <i>Reviews in Medical Virology</i> , 2023, 33, . | 3.9 | 7 |
| 279 | Dynamics of Antibody Responses after Asymptomatic and Mild to Moderate SARS-CoV-2 Infections: Real-World Data in a Resource-Limited Country. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 185. | 0.9 | 0 |
| 280 | In-depth characterization of long-term humoral and cellular immune responses to COVID-19 mRNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 72, 104616. | 0.9 | 2 |
| 281 | Blood Biomarkers from the Emergency Department Disclose Severe Omicron COVID-19-Associated Outcomes. <i>Microorganisms</i> , 2023, 11, 925. | 1.6 | 1 |
| 282 | Factors associated with not receiving the primary series and booster dose of the COVID-19 vaccine among Venezuelan migrants in Peru: A population-based cross-sectional study. <i>Travel Medicine and Infectious Disease</i> , 2023, 53, 102563. | 1.5 | 2 |
| 283 | Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination. <i>European Journal of Medicinal Chemistry</i> , 2023, 253, 115311. | 2.6 | 5 |
| 284 | Immunoregulatory actions of calf thymus extract (TFX®) in vitro in relation to its effect on expression of mitogen activated protein kinases. <i>International Immunopharmacology</i> , 2023, 118, 109995. | 1.7 | 0 |
| 285 | Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2 monoclonal antibody. <i>Antiviral Research</i> , 2023, 211, 105546. | 1.9 | 2 |
| 286 | Exploration of Fuzheng Yugan Mixture on COVID-19 based on network pharmacology and molecular docking. <i>Medicine (United States)</i> , 2023, 102, e32693. | 0.4 | 6 |
| 287 | Understanding the mechanisms for COVID-19 vaccine's protection against infection and severe disease. <i>Expert Review of Vaccines</i> , 2023, 22, 186-192. | 2.0 | 6 |
| 288 | Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation. <i>Microorganisms</i> , 2023, 11, 368. | 1.6 | 2 |
| 290 | PEGylation Prolongs the Half-Life of Equine Anti-SARS-CoV-2 Specific F(ab') ₂ . <i>International Journal of Molecular Sciences</i> , 2023, 24, 3387. | 1.8 | 0 |
| 291 | Global pattern and determinants of coronavirus disease 2019 (COVID-19) vaccine coverage and progression: a global ecological study. <i>Global Health Journal (Amsterdam, Netherlands)</i> , 2023, 7, 18-23. | 1.9 | 6 |
| 293 | Efficacy of vaccination against the SARS-CoV-2 virus in patients with chronic kidney disease on hemodialysis. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, . | 1.4 | 3 |
| 294 | Case report: First manifestation of multiple sclerosis temporally correlated with COVID-19 vaccination. <i>Frontiers in Neurology</i> , 0, 14, . | 1.1 | 5 |
| 295 | The impact of COVID-19 and COVID vaccination on cardiovascular outcomes. <i>European Heart Journal Supplements</i> , 2023, 25, A42-A49. | 0.0 | 10 |
| 296 | Efficacy, Safety and Immunogenicity of Anti-SARS-CoV-2 Vaccines in Patients with Cirrhosis: A Narrative Review. <i>Vaccines</i> , 2023, 11, 452. | 2.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 297 | Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2023, 10, . | 3.1 | 3 |
| 298 | Coronavirus disease 2019 vaccines: challenges of using global mass vaccination to achieve herd immunity. <i>Chinese Medical Journal</i> , 0, Publish Ahead of Print, . | 0.9 | 0 |
| 299 | Evolution of antibody profiles against SARS-CoV-2 in experienced and naïve vaccinated elderly people. <i>Frontiers in Immunology</i> , 0, 14, . | 2.2 | 1 |
| 300 | Independent control of COVID-19 vaccines by EU Official Control Authority Batch Release: challenges, strengths and successes. <i>Npj Vaccines</i> , 2023, 8, . | 2.9 | 1 |
| 301 | Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4401. | 1.8 | 4 |
| 302 | Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 72, 104582. | 0.9 | 5 |
| 303 | Monitoring and immunogenicity of SARS-CoV-2 vaccination of laboratory rhesus monkeys (Macaca) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 | 1.6 | 1 |
| 304 | A Rare Single Case of COVID-19-Induced Acute Myocarditis and Encephalopathy Presenting Simultaneously. <i>Vaccines</i> , 2023, 11, 541. | 2.1 | 0 |
| 305 | Can Probiotics, Particularly <i>Limosilactobacillus fermentum</i> UCO-979C and <i>Lacticaseibacillus rhamnosus</i> UCO-25A, Be Preventive Alternatives against SARS-CoV-2?. <i>Biology</i> , 2023, 12, 384. | 1.3 | 2 |
| 306 | Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. <i>International Immunopharmacology</i> , 2023, 117, 109968. | 1.7 | 17 |
| 307 | Identification of genes related to immune enhancement caused by heterologous ChAdOx1â€“BNT162b2 vaccines in lymphocytes at single-cell resolution with machine learning methods. <i>Frontiers in Immunology</i> , 0, 14, . | 2.2 | 4 |
| 308 | Effect of religious fatalism and concern about new variants on the acceptance of COVID-19 vaccines. <i>Frontiers in Psychiatry</i> , 0, 14, . | 1.3 | 2 |
| 309 | Genesis, evolution and effectiveness of Singapore's national sorting logic and home recovery policies in handling the COVID-19 Delta and Omicron waves. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 35, 100719. | 1.3 | 4 |
| 310 | Solid Lipid Nanoparticles: Multitasking Nano-Carriers for Cancer Treatment. <i>Pharmaceutics</i> , 2023, 15, 831. | 2.0 | 8 |
| 311 | A useful tool for the safe diagnosis and control of the two main pandemics of the XXI century: COVID-19 and African Swine Fever disease. <i>PLoS ONE</i> , 2023, 18, e0282632. | 1.1 | 0 |
| 312 | COVID-19 Vaccination and the Development of Autoimmune Diseases. <i>Internal Medicine</i> , 2023, , . | 0.3 | 0 |
| 313 | Protein-based Nanoparticle Vaccine Approaches Against Infectious Diseases. <i>Archives of Medical Research</i> , 2023, 54, 168-175. | 1.5 | 3 |
| 314 | Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines. <i>Vaccines</i> , 2023, 11, 615. | 2.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 315 | Extracellular vesicles in COVID-19 prognosis, treatment, and vaccination: an update. <i>Applied Microbiology and Biotechnology</i> , 2023, 107, 2131-2141. | 1.7 | 4 |
| 316 | Risk and Benefit of mRNA COVID-19 Vaccines for the Omicron Variant by Age, Sex, and Presence of Comorbidity: A Quality-Adjusted Life Years Analysis. <i>American Journal of Epidemiology</i> , 2023, 192, 1137-1147. | 1.6 | 3 |
| 317 | The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5644. | 1.8 | 4 |
| 318 | Modeling the Spread of COVID-19 with the Control of Mixed Vaccine Types during the Pandemic in Thailand. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 175. | 0.9 | 1 |
| 319 | Immune responses of different COVID-19 vaccination strategies by analyzing single-cell RNA sequencing data from multiple tissues using machine learning methods. <i>Frontiers in Genetics</i> , 0, 14, . | 1.1 | 2 |
| 320 | Architecture of the SARS-CoV-2-specific T cell repertoire. <i>Frontiers in Immunology</i> , 0, 14, . | 2.2 | 2 |
| 321 | The Role of Folic Acid in SARS-CoV-2 Infection: An Intriguing Linkage under Investigation. <i>Journal of Personalized Medicine</i> , 2023, 13, 561. | 1.1 | 2 |
| 322 | Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19. <i>Frontiers in Immunology</i> , 0, 14, . | 2.2 | 3 |
| 323 | Organoids to Remodel SARS-CoV-2 Research: Updates, Limitations and Perspectives. , 2023, . | | 0 |
| 324 | SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison. <i>Diagnostics</i> , 2023, 13, 1194. | 1.3 | 2 |
| 325 | mRNA Vaccines against SARS-CoV-2: Advantages and Caveats. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5944. | 1.8 | 12 |
| 326 | Comparisons of lymphocytes profiles and inflammatory cytokines levels in blood of patients with differed severity of infection by human adenovirus type 7. <i>BMC Infectious Diseases</i> , 2023, 23, . | 1.3 | 0 |
| 327 | Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai. <i>Frontiers of Medicine</i> , 2023, 17, 562-575. | 1.5 | 8 |
| 328 | Glycan masking in vaccine design: Targets, immunogens and applications. <i>Frontiers in Immunology</i> , 0, 14, . | 2.2 | 3 |
| 329 | Analysis of application of covid-19 vaccine in Mexico city by age and gender groups in the second wave of the pandemic. <i>International Journal of Vaccines & Vaccination</i> , 2022, 7, 3-7. | 0.3 | 0 |
| 330 | Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study. <i>PLoS ONE</i> , 2023, 18, e0283529. | 1.1 | 0 |
| 331 | Mathematical Modeling Evaluates How Vaccinations Affected the Course of COVID-19 Disease Progression. <i>Vaccines</i> , 2023, 11, 722. | 2.1 | 3 |
| 332 | Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study. <i>Infection</i> , 2023, 51, 1093-1102. | 2.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 333 | A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge. <i>Scientific Reports</i> , 2023, 13, . | 1.6 | 2 |
| 334 | The Effect of the Immunization Schedule and Antibody Levels (Anti-S) on the Risk of SARS-CoV-2 Infection in a Large Cohort of Healthcare Workers in Northern Italy. <i>Vaccines</i> , 2023, 11, 746. | 2.1 | 4 |
| 335 | Effects of vaccines on clinical characteristics of convalescent adult patients infected with SARS-CoV-2 Omicron variant: A retrospective study. <i>Frontiers in Microbiology</i> , 0, 14, . | 1.5 | 0 |
| 336 | COVID-19 Induced Postural Orthostatic Tachycardia Syndrome (POTS): A Review. <i>Cureus</i> , 2023, , . | 0.2 | 9 |
| 337 | SARS-CoV-2 collective immunity among the population of the Republic of Armenia. <i>Russian Journal of Infection and Immunity</i> , 2023, 13, 75-90. | 0.2 | 1 |
| 338 | Clinical Characteristics and Outcomes of Vaccinated and Unvaccinated Pregnant Women Hospitalized With COVID-19: An Observational Study by Vaccination Status. <i>The Journal of Tepecik Education and Research Hospital</i> , 2023, 33, 120-127. | 0.2 | 0 |
| 339 | An assessment of the strategy and status of COVID-19 vaccination in India. <i>Immunologic Research</i> , 2023, 71, 565-577. | 1.3 | 3 |
| 340 | Construction and validation of a deterioration model for elderly COVID-19 Sub-variant BA.2 patients. <i>Frontiers in Medicine</i> , 0, 10, . | 1.2 | 0 |
| 341 | Efficacy of Six Different SARS-CoV-2 Vaccines during a Six-Month Follow-Up and Five COVID-19 Waves in Brazil and Mexico. <i>Vaccines</i> , 2023, 11, 842. | 2.1 | 0 |
| 342 | Temporal association between COVID-19 vaccination and Raynaud's phenomenon: A case series. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, . | 1.4 | 2 |
| 343 | Clinical Course of 53 Previously Vaccinated Patients Admitted to the National Hospital in Warsaw, Poland with COVID-19 Between November 2021 and March 2022. <i>Medical Science Monitor</i> , 0, 29, . | 0.5 | 0 |
| 344 | Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination. <i>Cancers</i> , 2023, 15, 2344. | 1.7 | 0 |
| 345 | A machine learning model for predicting serum neutralizing activity against Omicron SARS-CoV-2 BA.2 and BA.4/5 sublineages in the general population. <i>Journal of Medical Virology</i> , 2023, 95, . | 2.5 | 2 |
| 346 | BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai. <i>Vaccine</i> , 2023, , . | 1.7 | 2 |
| 347 | Effectiveness of Heterologous COVID-19 Vaccine Booster in Korean Elderly Population, 2022. <i>Journal of Korean Medical Science</i> , 2023, 38, . | 1.1 | 0 |
| 348 | mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals. <i>Frontiers in Immunology</i> , 0, 14, . | 2.2 | 2 |
| 363 | Antiviral strategy. , 2023, , 89-95. | | 0 |
| 366 | COVID-19 Pandemic: Outbreak, <i>Epidemiology and Immunology</i> . , 2023, , 1-21. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 384 | Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies. <i>Communications Medicine</i> , 2023, 3, . | 1.9 | 7 |
| 419 | Efficacy of inactivated SARS-CoV-2 vaccination in pediatric hematology/oncology patients: a real-world study. <i>World Journal of Pediatrics</i> , 0, , . | 0.8 | 0 |
| 447 | Antiviral Phytocompounds Against Animal-to-Human Transmittable SARS-CoV-2. , 2023, , 189-224. | | 0 |
| 467 | Understanding the Omicron Variant in the COVID-19 Pandemic. , 0, , . | | 0 |
| 481 | Plant-Derived Natural Compounds as an Emerging Antiviral in Combating COVID-19. <i>Indian Journal of Microbiology</i> , 2023, 63, 429-446. | 1.5 | 1 |
| 505 | Managing COVID-19 Variants: Mapping Data from the International Clinical Trials Registry Platform. , 0, , . | | 1 |
| 513 | In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. , 2024, 21, 103-118. | | 4 |